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Circulating polymorphonuclear leukocytes (PMN) 
from patients with psoriasis and psoriatic arthritis were 
fo und to be significantly more adherent to nylon fiber 
columns when compared with both normal and nonpso-
riatic patient control groups. The increased adherence 
correlated positively with the extent of disease and was 
highest in those patients with psoriatic arthritis. Total 
leukocyte and PMN counts were increased in psoriasis 
patients and were highest in the psoriatic arthritis 
group. No increase in cell counts was found for mono-
nuclear leukocytes. PMN adherence was not increased 
in lithium-treated patients or a nonpsoriatic patient con-
trol group although such patients did have significant 
granulocytosis. PMN's are frequently present in lesions 
of psoriasis as are activated complement components 
and abnormal keratinocyte cyclic nucleotide levels. 
These factors or others may cause a generalized activa-
tion of PMN's in psoriasis leading to migration of neu-
trophils into the skin lesion. The present study demon-
strates a systemic effector cell alteration in psoriasis and 
contradicts the general concept that uncomplicated pso-
riasis is limited to the skin. 
Polymorphonuclear leukocytes (PMN) have been shown to 
have increased adherence to nylon wool fibers in certain inflam-
matory diseases, such as vasculitis, rheumatoid arthritis, sys-
temic lupus erythematosus, acute myocardial infarction, pneu-
monia, osteomyelitis and pyeloneplu-itis [1,2]. A similar increase 
in PMN adherence is seen in hemodialysis patients in whom a 
transient leukopenia and clumping in the pulmonary vascula-
ture is produced by the activation of C5a [3,4]. 
Psoriasis is an idiopathic disorder of the skin and occasionally 
t he joints in which PMN's are frequently a prominent feature 
of the epidermal inflltrate [5]. The role PMN's play in the 
initiation and course of the disease is not yet understood, but it 
may be depe ndent on locally released chemotactic factors. 
Immunoglobulin (6] and complement dependent chemotactic 
factors [7,8] have been ide ntified in psoriatic lesions, and serum 
immunoglobulin levels are increased as well (9]. 
In the present study, we have found that circulating PMN's 
from both psoriasis and psoriatic arthritis patients have an 
increased in vitro adherence to nylon fiber columns and that 
the magnitude of this adherence increases with the extent of 
t heir disease. 
MATERIALS AND METHODS 
Patients 
Twenty-eight patients were selected from a county hospital outpa-
tient dermatology clinic (Pru·kland Memorial Hospital) and from a 
medical school private outpatient clinic. Patients were selected ran-
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dornly to represent a continuum of disease severity and the extent of 
their cutaneous disease was evaluated by one of us (P.R.B.) prior to 
their adherence study. Patients were categorized as having minimal, 
moderate Ot extensive cutaneous involvement; minimal was limited to 
the elbows, knees or scalp; moderate included multiple skin surface and 
as much as 20% of the total body surface; extensive included all patients 
with more than 20% of the body surface involved. The 6 patients with 
arthri tis had symmetrical involvement of their distal interphalangeal 
joints as well as extensive skin involvement. No patients were receiving 
systemic medication at the t ime of the study. Informed consent was 
obtained from all patients prior to venipuncture. 
Controls 
Twenty-eight healthy volunteers with no history of psoriasis or 
chronic skin disease were used as normal controls. The nonpsoriatic 
patient control group consisted of 10 otherwise normal volunteers with 
acute sunbum (7 patients) or poison ivy contact dermatitis (3 patients) 
of varied severity, including 4 with minimal, 4 with moderate and 2 
with extensive cutaneous involvement. These patients were studied 24-
48 hr after exposure. None of the volunteers in the control groups were 
receiving systemic or topical medication at the ,time of the study. 
Six patients treated with lithium carbonate were obtained from a 
county hospital psychiatric clinic and from a private outpatient clinic. 
Consent was obtained from both patient and attending psychiatrist 
prior to venipuncture. 
Adherence Assay 
PMN adherence was measured according to the method of Mac-
Gregor, Spagnuolo, and Lentnek (10]. Adherence columns were pre-
pru·ed by packing 50 (±.5) rng of nylon fiber (3-denier, 4-cm, Type 200, 
Fenwal Laboratories, Deru·field, Illinois) to a length of 15 mm in 23 ern 
pasteur pipettes. Pipette tips were placed in glass tubes and incubated 
at 37°C. All glasswru·e was siliconized (Siliclad, PCR Research, Inc. , 
Gainesville, Florida) prior to use. 
Heparinized (B-D Vacutainer #4716) venous blood was drawn from 
28 psoriasis patients, including 6 patients with psoriatic arthritis, and 
38 control donors, and within 1 h.r, l ml of whole blood was put on an 
adherence column and allowed to run through by gravity flow. White 
cell counts (Model D2 Coulter Counter) and differentials were per-
formed before and after t he blood passed tluough the nylon fiber 
columns. The percent PMN adherence was calculated as follows: 
m 1erence = 1 - X 100 01 PMN Adl ( % PMN after column ) 
% PMN before column 
For each subject, PMN adherence was the mean of triplicate deter-
minations. 
Statistical Methods 
Because of skewed distribu tion, nonparametic analysis with the 
Mrum Whitney U-test was used to determine the significance of differ-
ences between psoriatic and control groups. Parametric analyses were 
also done and the results were similar. 
RESULTS 
PMN Adherence 
PMN adherence for patients and control groups is illustrated 
in Fig 1. The m ean PMN adherence for 28 normal controls was 
19.2% ± 1.8 (SEM) and for 28 psoriatic donors it was 33.9% ± 
2.7. This difference was highly significant (P < .001, Mann 
Whitney U-Test) . When the 6 patients with cuta neous psoriasis 
and psoriatic ru·th.ritis were r emoved from those with cutaneous 
involvement alone, the percent PMN adherence was 31.4 ± 3.0 
and still significantly different from normal controls (P < .001). 
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FIG l. P ercent PMN adherence for control and psonas1s groups. 
Horizontal bars represent the mean for each group. n.s. = not statis-
tically significant. 
The 10 nonpsoriatic patient controls, consisting of 7 sunburn 
and 3 contact dermatitis patients, had a mean PMN adherence 
of 16.3% ·± 3.0. This was not significantly different from the 
normal controls but was decreased from the psoriatic group (P 
< .001). 
On initial examination, patients were categorized by the 
extent of their disease. The mean PMN adherence values 
stratified according to the extent of disease are shown in Fig 2. 
Nine patients with minimal or no apparent disease had a mean 
PMN adherence of 26.2% ± 4.9, five with moderate psoriasis 
had a mean PMN adherence of29.6% ± 3.3, and 8 with extensive 
disease had an · adherence of 37.5% ± 5.4. The 6 patients with 
psoriatic arthritis were categorized separately and had the 
highest adherence of 43.3% ± 5.0. A stepwise increase in adher-
ence occurs with each category. Three of the 4 psoriasis groups, 
those with moderate and extensive disease and with psoriatic 
arthritis were significantly higher (P < .03) than the normal 
controls. The psoriatic arthritis group was also significantly 
increased over the minimal psoriasis group (P < .03). 
Each of the individual psoriasis groups was significantly 
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increased (P < .04) over the nonpsoriatic patient controls, 
whose extent of disease ranged from minimal to extensive 
involvement. 
Leukocyte Counts 
Total leukocyte (WBC) counts in heparinized blood were 
found to be significantly increased (P < .001) in the psoriasis 
patients when compared with normal controls. To standardize 
the leukocyte counts and to allow comparison with other re-
ports, ethylenediaminetetraacetate (EDT A) was used as the 
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FIG 2. Percent PMN adherence for normal controls, psoriatic ar-
thritis patients and psoriasis patients according to extent of disease. 
Horizontal bars represent the mean for each group. 
TABLE I. WBC, PMN and mononuclear cell counts for control and patient groups 
Study 
groups n" 
WBC/rnm" PMN/rnrn" Monos/rnrn" (X l O- ' ) P value (xlO- ") P value (xiO- ") 
Control 
Normal 
Patient 
Psoriasis 
Total 
Extent 
19 
9 
22 
6.2 
8.5 
8.7 
Minimal 7 8.1 
Moderate 5 7. 7 
Extensive 4 7.6 
Psoriatic 6 10.4 
Arthritis 
"n =Number studied. 
• n.s. = not statistically significant. 
., 
<".001 
l 
n.s.11 
J 
l 3.2 ., l 2.9 5.0 "'S .005 3.5 
< .001 l < .001 
J n.s. J 5.6 J 3.0 
4.8 2.7 
5.1 2.6 
4.5 3.2 
7.6 2.8 
., 
~.s. 
l 
n.s. 
J 
P value 
l 
n.s. 
J 
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anticoagulant for the reported WBC determinations (Table I). 
When leukocyte counts were divided into granulocytes and 
mononuclear cells, the increased cell counts were confined 
totally to granulocytes. The absolute PMN count of 5.6 ± 0.4 
(X lO:Jmm- 3) for patients with psoriasis was significantly higher 
(P < .001) than the normal controls of 3.2 ± 0.2 (X 103mm- 3). 
Removing the psoriatic arthritis patients from the psoriasis 
group slightly lowered the WBC and PMN counts but did not 
change the significance of the difference when compared to 
normal controls. 
Total WBC's and PMN cell counts in the nonpsoriatic patient 
controls were also significantly higher (P < .001 and < .005 
respectively) than in normal controls, but were not statistically 
different from the psoriasis patients. The number of mononu-
clear cells in each group was not different. 
A stepwise increase with the extent of disease was not found 
for PMN counts as it was with percent PMN adherence. As 
with PMN adherence, the greatest increase in numbers ofWBC 
and PMN was found in those patients with psoriatic arthritis. 
This group had a mean PMN count of 7.6 ± 0.6 (X 103mm- 3), 
which was significantly increased over the normal controls (P 
< .001), the nonpsoriatic patient controls (P < .05) and the 
patients with psoriasis alone (P < .005). 
Using a regression analysis, percent PMN adherence for the 
control and psoriasis groups was analyzed with the WBC, PMN 
and mononuclear cell counts. No conelation was found between 
PMN adherence and the various cell numbers for any of the 
groups. 
PMN Adherence in Lithium Treated Patients 
In an additional determination of the effect of increased 
granulocyte release into the circulation, PMN adherence and 
cell counts were measured in lithium-treated psychiatric pa-
tients. Lithium cru·bonate therapy has been shown to produce 
a granulocytosis in such patients (11,12] and in healthy volun-
teers (13] and to aggravate psoriasis (14]. Six nonpsoriatic 
patients receiving lithium were studied and the mean values 
were compared with normal controls and psoriatic patients as 
shown in Table II. Although total leukocyte (P < .01) and PMN 
counts (P < .002) were significantly increased over the normal 
controls, the mean PMN adherence, 17.5%, was not different 
from the normal mean, 19.2%. There was no difference in 
mononuclear cell counts. 
DISCUSSION 
Psoriasis is characterized clinically by multiple circumscribed 
red plaques which are covered with scales. Characteristic his-
topathologic changes occur in the epidermis and superficial 
TABLE II. PMN adherence and leulwcyte counts for lithium 
patients as compared to normal and psoriatic donors 
Studies Normal P" Lithium P'' Psoriatic controls patients patients 
nc 28 6 28 
% PMN 19.2 n.s.d 17.5 <.001 33.9 
adherence 
WBC/mmj 6.2 < .01 8.9 n.s. 8.7 
(xlO- ") 
PMN/ mm3 3.2 <.002 6.0 n.s. 5.6 
(xlO- ") 
Monos/ mm" 2.9 n.s. 2.8 n .s. 3.0 
(x10- 'J) 
"P values represent significance of difference between normal ·con-
trols and lithium patients. 
6 P values represent significance of difference between psoriatics and 
lithium patients. 
c n = Number studied for adherence means. For the ceU counts n = 
19, for normal controls, 6 for lithium tre.ated patients and.22 for psoriasis 
patients. 
d n.s. = Not statistically significant. 
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dermis [15]. For these reasons the thrust of recent investigation 
into the pathogenesis of psoriasis has been directed at the 
epidermis and has included cell cycle control and biochemical 
modulators of epidermal proliferation [16,17]. Such studies 
have not been reconciled with extracutaneous manifestations 
which may occur, such as psoriatic arthritis and the leukocytosis 
and fever of pustular psoriasis. Also not fully explained is the 
frequent accumulation of PMN's within plaques of psoriasis, 
although both complement activation by antistratum corneum 
antibodies [18] and nonimmunologic complement activation by 
neutral protease [7] have been identified in these areas. To 
determine whether there is a more generalized alteration in 
PMN function in psoriasis we determined PMN adherence and 
circulating PMN levels in patients with psoriasis. 
Circulating polymorphonucleru· leukocytes from 22 patients 
with psoriasis and 6 with psoriatic arthritis exhibited increased 
in vitro adherence to nylon fibers. Adherence conelated posi-
tively with the clinical extent of disease. However, this increased 
PMN adherence was not diagnostic since patient groups and 
controls exhibited some overlap. 
Patients with acute sunburn or with acute poison ivy contact 
dermatitis had normal PMN adherence even though they had 
significant skin involvement. Eaglstein, Sakai, and Mizuno (19] 
have reported that leukocytes, particularly PMN's may make 
the major contribution to both the inflammation and erythema 
which occur 24 hr after acute sunburn. Thus, in 2 cutaneous 
inflammatory skin conditions, one of which is probably PMN 
mediated, no increased PMN adherence occuned. 
Psoriasis patients were also found to have a significant gran-
ulocytosis when compared to normal controls. Whether this 
increased release of PMN's into the circulation is a primary or 
secondary event in psoriasis is not known, but it does not appear 
to correlate with extent of disease or PMN adherence. Psychi-
atric patients treated with lithium carbonate and nonpsoriatic 
patient controls also exhibited a granulocytosis, but their PMN 
adherence was not elevated. Similar fmdings for lithium pa-
tients have been reported by MacGregor and Dyson [20] who 
observed that such patients had normal or slightly decreased 
PMN adherence. 
Complement activation may play a role in increasing PMN 
adherence in psoriasis. Fehr and Jacob [21] have reported that 
both in vitro PMN adherence and in vivo mru·gination were 
increased in the presence of activated complement components, 
and that these 2 processes are closely related. In similar exper-
iments, O'Flaherty and co-workers [22] showed that 6 in vitro 
chemotactic agents, including activated autologous plasma, 
trypsinized C5 and C5 chemotactic factor, induced transient in 
vivo neutropenia in rabbits. It has been shown that soluble 
extracts from psoriatic scales contain a PMN chemotactic factor 
that is complement dependent (7,8]. Thus, in psoriatic lesions, 
activated complement components may cause localized PMN 
chemotaxis and deposition in the skin. These or other comple-
ment fragments may also diffuse from the epidermis to make 
the circulating PMN's more adherent. 
An imbalance in the cyclic AMP / cyclic GMP ratio in the 
psoriatic lesions [23,24] suggests that the 2 nucleotides are 
important factors in psoriatic epidermal changes. Both these 
results and oms are consistent with reports by MacGregor and 
co-workers [25,26] on the in vitro. effect of cyclic nucleotides on 
PMN adherence. The instability in the cyclic AMP / cyclic GMP 
ratio, which has been proposed for psoriasis, may not be limited 
to the skin but may reflect a more generalized defect which 
would include PMN function. 
Based on these considerations, we propose that psoriasis is a 
systemic disease in which increased numbers of granulocytes 
are released into the circulation. While in the blood the PMN's 
are altered and become more adherent. The PMN's may then 
undergo increased margination and, due possibly to locally 
released chemotactic factor(s) from the active psoriatic lesions, 
the PMN's migrate through the dermal vessel walls and deposit 
in the epidermis. 
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Studies of both complement activation and PMN cyclic nu-
cleotide levels are needed to characterize these systemic mani-
festations of psoriasis. 
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Statement of Committee for Dermatopathology 
·The Committee for Dermatopathology, with full concurrence of The American Board of Dermatology 
and The American Board of Pathology, announces a change in one of the prerequisites for qualification 
for the examination for special competence in dermatopathology based on experience in dermatopathol-
ogy. The Dermatopathology Credentials Committee will consider applications from persons who hold a 
basic certificate from The American Board of Dermatology or The American Board of Pathology 
(anatomic pathology, or anatomic and clinical pathology) and 2 yr of experience in dermatopf!.thology 
acceptable to the Committee for Dermatopathology. The training requirements for basic certification 
must have been completed before December 31, 1977, and the 2 yr of acceptable experience in dermato-
pathology must have been completed before December 31, 1979. The final expiration date for applications 
under this prerequisite is December 31, 1981. Other qualifications to take the dermatopathology exami-
nation remain as stated in the Requirements for Certification in the Directory of Residency Training 
Programs. Persons who believe they may qualify for the special competence examination in dermato-
pathology as a result of this change should request an application form from the office of either The 
American Board of Dermatology or The American Board of Pathology. 
